Ladies and Gentlemen,
we invite you to participate in a free webinar “Advances in diagnostics and therapy of melanoma and other skin cancers”.


Subject of the first meeting

Difficult scenarios in metastatic melanomas — fast progressors, mucosal melanoma, relapse after adjuvant therapy, unknown primary melanoma, brain metastases, toxicity leading to treatment withdrawal



April 27, at 4:30 p.m..



Piotr RutkowskiProf. Piotr Rutkowski, MD, PhD

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland


Piotr Rutkowski is Professor of Surgical Oncology at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland.

Dr Rutkowski is the current Head of the Department of Soft Tissue/Bone Sarcoma and Melanoma, the Deputy Director of Institute for National Oncological Strategy and Clinical Trials at the Maria Sklodowska-Curie National Research Institute of Oncology. He has participated in several investigator-driven trials in melanoma and sarcoma. He is also Coordinator of the Polish Clinical GIST Registry, and a reviewer for several international scientific journals, as well as a member of the Editorial Board of Annals of Surgical Oncology and European Journal of Surgical Oncology.

Dr Rutkowski is an active member of the EORTC Melanoma Group; EORTC Soft Tissue and Bone Sarcoma Group, where he chaired the Local Treatment Subcommittee and the Membership Committee of the EORTC Board. He is a member of several Polish and international scientific societies (President Elect of Polish Oncological Society, Board member of Polish Society Surgical Oncology, Ex-member of the Board of Directors of the Connective Tissue Oncology Society, member of International Affair Committee of ASCO, Global Curriculum Committee of ESMO). Dr Rutkowski has authored or co-authored over 500 scientific papers in Polish and international journals (with an impact factor of above 4000, index-H: 65, citation index >30000, rewarded Highly Cited Researcher in Clinical Medicine 2021), and is co-author of national and international recommendations for sarcoma and melanoma. He is working very closely with national patient advocacy groups for GIST/sarcoma and melanoma, coordinating Polish Clinical GIST Registry and is Chairman of the Melanoma Academy in Poland. Member of Council of Agency of Medical Research. Chair of Task Group of Ministry of Health, Poland for National Oncological Strategy.


Mario MandalaProf. Mario Mandalà

Prof. Mario Mandalà received his medical degree from the Faculty of Medicine, Catholic University of Rome, Italy. He completed residency trainings in Medical Oncology and Haematology and since then he has consistently been active in medical research. He is currently associate professor of Medical Oncology at the University of Perugia. In this position, he coordinates prospective outcome research projects and several clinical trials investigating new therapeutic strategies (including target therapies and immunotherapies) in melanoma and gastrointestinal cancer patients.

He was recently appointed Coordinator of the Mucosal and Ocular Melanoma Section of the Italian Rare Cancers Network.

Since 2011, he chaired the scientific and organizing committees of the Clinical and Translational Research Working Group of the Italian Melanoma Intergroup (IMI). Since 2019 Prof. Mandalà is President Elect of IMI. Since 2021 he is Secretary of the EORTC melanoma group.

He is full member of the European Society of Medical Oncology. He is Reviewer for several scientific journals, including Lancet Oncology, Cancer, British Journal of Cancer, Journal of Clinical Oncology, European journal of cancer, Annals of Oncology, Cancer Treatment Review, Journal of Thrombosis and Haemostasis, Thrombosis and Haemostasis, Arteriosclerosis-Thrombosis and Vascular Biology, Critical Reviews in Oncology and Haematology. He has authored more than 190 publications and his major scientific interests are clinical and translational research on melanoma, gastrointestinal cancer and thromboembolic complications in cancer patients. Since 2008, he gave major contributions in ESMO, AIOM and ISTH clinical practice guidelines on the management of venous thromboembolism and solid tumours.



Mario Mandala

Hanna Koseła-Paterczyk

Alice Indini

Copyrights © 2023 Via Medica